XML 191 R28.htm IDEA: XBRL DOCUMENT v3.22.1

Capital Management	12 Months Ended
	Dec. 31, 2021
Disclosure Of Capital Management [Abstract]
Capital Management	23. Capital Management The Company's capital management objectives are to maintain financial flexibility in order to complete the pharmaceutical research and development programs centered on the lead compounds, FSD-PEA, Lucid-PSYCH and LUCID-MS. The Company defines capital as the aggregate of its capital stock and borrowings. As at December 31, 2021, the Company's Share Capital was $152,324,677 (2020 - $103,208,126) The Company does not have any long-term debt. Outstanding Notes payable were assumed on acquisition of Prismic and are due on demand. The Company manages its capital structure in accordance with changes in economic conditions. In order to maintain or adjust its capital structure, the Company may elect to issue or repay financial liabilities, issue shares, repurchase shares or undertake any other activities as deemed appropriate under the specific circumstances. The Company is not subject to any externally imposed capital requirements.

X

- References

No definition available.

+ Details

Name:	huge_DisclosureOfCapitalManagementAbstract
Namespace Prefix:	huge_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 134
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_134&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration